Objectives: We sought to determine the antiatherosclerotic properties of pioglitazone using multimethod noninvasive imaging techniques. Background: Inflammation is an essential component of vulnerable or high-risk atheromas. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, possesses potent anti-inflammatory properties. We aimed to quantify noninvasively the anti-inflammatory effects of pioglitazone on atheroma using 18F-fluorodeoxyglucose ( 18F-FDG) positron emission tomography (PET)/computed tomography (CT) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI). Methods: Atherosclerotic plaques were induced in the aorta of 15 New Zealand white rabbits by a combination of a hyperlipidemic diet and 2 balloon endothelial denudations. Nine rabbits continued the same diet, whereas 6 rabbits received pioglitazone (10 mg/kg orally) in addition to the diet. Twelve animals underwent 18F-FDG- PET/CT, and 15 animals underwent DCE-MRI at baseline, 1 month, and 3 months after treatment initiation. Concomitantly, serum metabolic parameters were monitored. After imaging was completed, aortic histologic analysis and correlation analysis were performed. Results: The 18F-FDG-PET/CT imaging detected an increase in average standardized uptake value in the control group (p < 0.01), indicating progressive inflammation, whereas stable standardized uptake values were observed in the treatment group, indicating no progression. The DCE-MRI analysis detected a significant decrease in the area under the curve for the pioglitazone group (p < 0.01). Immunohistologic examination of the aortas demonstrated a significant decrease in macrophage and oxidized phospholipid immunoreactivity in the pioglitazone group (p = 0.04 and p = 0.01, respectively) with respect to control animals, underlining the imaging results. Serum metabolic parameters showed no difference between groups. Strong positive correlations between standardized uptake value and macrophage density and between area under the curve and neovessels were detected (r 2 = 0.86 and p < 0.0001, and r 2 = 0.66 and p = 0.004, respectively). Conclusions: Both 18F-FDG-PET/CT and DCE-MRI demonstrate noninvasively the anti-inflammatory effects of pioglitazone on atheroma. Both imaging methods seem suited to monitor inflammation in atherosclerosis.

Original languageEnglish
Pages (from-to)1100-1109
Number of pages10
JournalJACC: Cardiovascular Imaging
Issue number10
StatePublished - Oct 2011


  • F-fluorodeoxyglucose positron emission tomography/computed tomography
  • atherosclerosis
  • dynamic contrast-enhanced magnetic resonance imaging
  • inflammation
  • pioglitazone


Dive into the research topics of 'Pioglitazone modulates vascular inflammation in atherosclerotic rabbits: Noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging'. Together they form a unique fingerprint.

Cite this